Douglas Bruce1, John P Brady2, Elissa Foster3, Mona Shattell4. 1. 1 Department of Health Sciences, DePaul University , Chicago, IL. 2. 2 Department of Psychology, DePaul University , Chicago, IL. 3. 3 Health Communication Program, College of Communication, DePaul University , Chicago, IL. 4. 4 Department of Community, Systems, and Mental Health Nursing, College of Nursing, Rush University , Chicago, IL.
Abstract
OBJECTIVES: Despite expanded legalization and utilization of medical cannabis (MC) internationally, there is a lack of patient-centered data on how MC is used by persons living with chronic conditions in tandem with or instead of prescription medications. This study describes approaches to use of MC vis-à-vis prescription medications in the treatment of selected chronic conditions. DESIGN: Participants completed semistructured telephone interviews with open-ended questions. Content analysis of qualitative data identified themes and subthemes relating to patient approaches to using MC products. PARTICIPANTS: Thirty persons (mean age = 44.6 years) living with a range of chronic conditions (e.g., rheumatoid arthritis, Crohn's disease, spinal cord injury/disease, and cancer) who had qualified for and used MC in Illinois. RESULTS: Participants described a range of approaches to using MC, including (1) as alternatives to using prescription or over-the-counter medications; (2) complementary use with prescription medications; and (3) as a means for tapering off prescription medications. Motives reported for reducing or eliminating prescription medications included concerns regarding toxicity, dependence, and tolerance, and perceptions that MC improves management of certain symptoms and has quicker action and longer lasting effects. CONCLUSIONS: MC appears to serve as both a complementary method for symptom management and treatment of medication side-effects associated with certain chronic conditions, and as an alternative method for treatment of pain, seizures, and inflammation in this population. Additional patient-centered research is needed to identify specific dosing patterns of MC products associated with symptom alleviation and produce longitudinal data assessing chronic disease outcomes with MC use.
OBJECTIVES: Despite expanded legalization and utilization of medical cannabis (MC) internationally, there is a lack of patient-centered data on how MC is used by persons living with chronic conditions in tandem with or instead of prescription medications. This study describes approaches to use of MC vis-à-vis prescription medications in the treatment of selected chronic conditions. DESIGN:Participants completed semistructured telephone interviews with open-ended questions. Content analysis of qualitative data identified themes and subthemes relating to patient approaches to using MC products. PARTICIPANTS: Thirty persons (mean age = 44.6 years) living with a range of chronic conditions (e.g., rheumatoid arthritis, Crohn's disease, spinal cord injury/disease, and cancer) who had qualified for and used MC in Illinois. RESULTS:Participants described a range of approaches to using MC, including (1) as alternatives to using prescription or over-the-counter medications; (2) complementary use with prescription medications; and (3) as a means for tapering off prescription medications. Motives reported for reducing or eliminating prescription medications included concerns regarding toxicity, dependence, and tolerance, and perceptions that MC improves management of certain symptoms and has quicker action and longer lasting effects. CONCLUSIONS: MC appears to serve as both a complementary method for symptom management and treatment of medication side-effects associated with certain chronic conditions, and as an alternative method for treatment of pain, seizures, and inflammation in this population. Additional patient-centered research is needed to identify specific dosing patterns of MC products associated with symptom alleviation and produce longitudinal data assessing chronic disease outcomes with MC use.
Entities:
Keywords:
cannabis/cannabinoids; harm reduction; medical marijuana; pain; symptom management
Authors: Alana Mercurio; Elizabeth R Aston; Kasey R Claborn; Katherine Waye; Rochelle K Rosen Journal: Subst Use Misuse Date: 2019-06-10 Impact factor: 2.164
Authors: John S Luque; Arinze Nkemdirim Okere; Carlos A Reyes-Ortiz; Paula M Williams Journal: Complement Ther Med Date: 2021-01-15 Impact factor: 2.446
Authors: Kylie J Nabata; Emmanuel K Tse; Tom E Nightingale; Amanda H X Lee; Janice J Eng; Matthew Querée; Matthias Walter; Andrei V Krassioukov Journal: Curr Neuropharmacol Date: 2021 Impact factor: 7.363
Authors: Linan Zeng; Lyubov Lytvyn; Xiaoqin Wang; Natasha Kithulegoda; Silvana Agterberg; Yaad Shergill; Meisam Abdar Esfahani; Anja Fog Heen; Thomas Agoritsas; Gordon H Guyatt; Jason W Busse Journal: BMJ Open Date: 2021-09-07 Impact factor: 2.692
Authors: Anees Bahji; Natasha Breward; Whitney Duff; Nafisa Absher; Scott B Patten; Jane Alcorn; Darrell D Mousseau Journal: J Cannabis Res Date: 2022-03-14